Protein Dynamic Solutions key facts
as of Oct 2026- Developer of a high-throughput analytical platform designed to offer critical quality attribute (CQA) analysis.
- Protein Dynamic Solutions is valued at approximately $2.9M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $10.1M across 3 recorded rounds; the latest was Seed Round ($610K) in Jan 2020.
- Notable investors include US National Science Foundation, X-Square Capital, Antoine de Marsily, Aurdoro PR Holdings, Broadside — 15 tracked in total.
- Protein Dynamic Solutions has filed 3 Form Ds with the SEC since 2018, most recently Feb 2020 ($610K sold to 15 investors).
- Status: Privately Held (backing).
Valued at $2.9M at its later-stage round, Nov 2025. Nothing has traded since.
- ·The complete investor list: 15 names
- ·Watch Protein Dynamic Solutions: the Monday email on marks, rounds and moves
Protein Dynamic Solutions funding rounds
3 roundsWho backs Protein Dynamic Solutions
15+Protein Dynamic Solutions valuation
Protein Dynamic Solutions was valued at $2.9 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Protein Dynamic Solutions raised?
Protein Dynamic Solutions has raised $10.1 million in total; 3 of its rounds are on record, from 2016 on. The largest on record was a $610,000 seed round in Jan 2020.
Protein Dynamic Solutions has filed 3 Form Ds with the SEC since 2018, most recently in Feb 2020 ($610,000 sold to 15 investors).
Protein Dynamic Solutions investors
15 investors are on record for Protein Dynamic Solutions, including US National Science Foundation, X-Square Capital, Antoine de Marsily and Aurdoro PR Holdings. The seed round in Jan 2020 drew 15 investors.
About Protein Dynamic Solutions
Developer of a high-throughput analytical platform designed to offer critical quality attribute (CQA) analysis. The company's platform uses hyperspectral imaging and advanced signal processing to evaluate protein stability, aggregation, identity, and binding interactions, enabling biopharmaceutical companies to reduce release testing, analysis times, and product inventory.
- Sector
- Healthcare
- HQ
- Wakefield, MA, United States
- Founded
- 2011
- Employees
- 9
- Website
- pdsbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.